PP153 A randomized, open-label phase ii study comparing a novel regimen of dose-dense docetaxel-cyclophosphamide alternating with epirubicin-cisplatin against anthracycline-taxane in early TNBC, stratified for the use of low-dose nivolumab (NEOPLANETx study)

Le résumé fourni par la source

Recent advances in early triple-negative breast cancer (TNBC) treatment have incorporated immune checkpoint inhibitors and carboplatin, notably in the KEYNOTE-522 trial, enhancing pathological complete response (pCR) and event-free survival. However, consistent benefits in overall survival are unclear, and carboplatin regimens often cause significant hematological toxicity. Additionally, the high cost of pembrolizumab limits its use severely in low- and middle-income countries (LMICs). Our study evaluates the efficacy and safety of a novel dose-dense regimen ddDCEP (alternating cycles of docetaxel-cyclophosphamide and epirubicin-cisplatin every 2 weeks).

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.